Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Tripeptides – e.g. – tripeptide thyroliberin – etc.
Reexamination Certificate
2004-02-20
2008-03-11
Gupta, Anish (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Tripeptides, e.g., tripeptide thyroliberin , etc.
C530S340000, C514S007600
Reexamination Certificate
active
07342095
ABSTRACT:
The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are peptidomimetics that inhibit STAT function. Peptidomimetics of the invention include compounds of the formula RY*L (where Y* represents phosphotyrosine), with the R group at the Y-1 position. Peptidomimetics of the invention disrupt Stat3 activation and function. Peptidomimetics of the invention significantly inhibit tumor cell growth and induce tumor cell death.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: WO98/12201 (1998-03-01), None
patent: WO98/12201 (1998-03-01), None
patent: WO98/12201 (1998-03-01), None
patent: WO 00/44774 (2000-08-01), None
patent: WO 00/44774 (2000-08-01), None
Turkson J, et al, “Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation,” J Biol Chem. Nov. 30, 2001;276(48):45443-55.
Dorlands Medical Dictionary Definition: http://www.mercksource.com/pp/us/cns/cns—hl—dorlands.jspzQzpgzEzzSzppdocszSzuszSzcommonzSzdorlandszSzdorlandzSzdmd—a—34zPzhtm.
Kitas, E. A. et al. Synthesis of O-Phosphotyrosine-containing Peptides. 3. Synthesis of H-Pro-Tyr(P)-Val-OH via Dimethyl Phosphate Protection and the Use of Improved Deprotection Procedures, J. Org. Chem., 1990, pp., 4181-4187, vol. 55.
Gibson, B. W. el al Liquid Secondary Ionization Mass Spectrometric Characterization of Two Synthetic Phosphotyrosine-containing Peptides/ J. Am. Chem. Soc., 1987, pp. 5343-5348, vol. 109.
Waldmann, H et al, “New enzymatic protecting group technique for the construction of peptides and glycopeptides and glycopeptides,” Biomedica Biochimica Acta (1991), vol. 50(10-11), S243-S248.
Akira, S. “Roles of STAT3 defined by tissue-specific gene targeting”Oncogene, 2000, pp. 2607-2611, vol. 19.
Becker, S. et al. “Three-dimensional structure of the Stat3β homodimer bound to DNA”Nature, Jul. 9, 1998, pp. 145-151, vol. 394.
Berg, T. et al. “Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts”PNAS, Mar. 19, 2002, pp. 3830-3835, vol. 99, No. 6.
Bowman, T. et al. “STATs in oncogenesis”Oncogene, 2000, pp. 2474-2488, vol. 19.
Bowman, T. et al. “Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis”PNAS, Jun. 19, 2001, pp. 7319-7324, vol. 98, No. 13.
Bromberg, J. et al. “Stat3 Activation Is Required for Cellular Transformation by v-src”Molecular and Cellular Biology, May 1998, pp. 2553-2558, vol. 18, No. 5.
Bromberg, J. et al. “The role of STATs in transcriptional control and their impact on cellular function”Oncogene, 2000, pp. 2468-2473, vol. 19.
Buettner, R. et al. “Activated STAT Signaling in Human Tumors Provides Novel Molecular Targets for Therapeutic Intervention”Clinical Cancer Research, Apr. 2002, pp. 945-954, vol. 8.
Catlett-Falcone, R. et al. “STAT proteins as novel targets for cancer therapy”Current Opinion in Oncology, 1999, pp. 490-496, vol. 11.
Catlett-Falcone, R. et al. “Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells”Immunity, Jan. 1999, pp. 105-115, vol. 10.
Chen, X. et al. “Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA”Cell, May 29, 1998, pp. 827-839, vol. 93.
Darnell, J. E., Jr. “STATs and Gene Regulation”Science, Sep. 12, 1997, pp. 1630-1635, vol. 277.
Darnell, J. E., Jr. “Transcription Factors As Targets For Cancer Therapy”Nat. Rev. Cancer, Oct. 2002, pp. 740-749, vol. 2.
Epling-Burnette, P. K. et al. “Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression”The Journal of Clinical Investigation, Feb. 2001, pp. 351-361, vol. 107, No. 3.
Frank, D. A. “STAT Signaling in the Pathogenesis and Treatment of Cancer”Molecular Medicine, 1999, pp. 432-456, vol. 5.
Garcia, R. et al. “Constitutive Activation of Stat3 in Fibroblasts Transformed by Diverse Oncoproteins and in Breast Carcinoma Cells”Cell Growth&Differentiation, Dec. 1997, pp. 1267-1276, vol. 8.
Garcia, R. et al. “Activation of STAT Transcription Factors in Oncogenic Tyrosine Kinase Signaling”Journal of Biomedical Science, 1998, pp. 79-85. vol. 5.
Garcia, R. et al. “Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells”Oncogene, 2001, pp. 2499-2513, vol. 20.
Gibson, B. W. et al. “Liquid Secondary Ionization Mass Spectrometric Characterization of Two Synthetic Phosphotyrosine-Containing Peptides”J. Am. Chem. Soc., 1987, pp. 5343-5348, vol. 109.
Gouilleux, F. et al. “Prolactin and Interleukin-2 Receptors in T Lymphocytes Signal through a MGF-STAT5-Like Transcription Factor”Endocrinology, 1995, pp. 5700-5708, vol. 136, No. 12.
Grandis, J. R. et al. “Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo”PNAS, Apr. 11, 2000, pp. 4227-4232, vol. 97, No. 8.
Hirano, T. et al. “Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors”Oncogene, 2000, pp. 2548-2556, vol. 19.
Horvath, C. M. “STAT proteins and transcriptional responses to extracellular signals”TIBS, Oct. 2000, pp. 496-502, vol. 25.
Johnson, P. J. et al. “Overexpressed pp60c-srcCan Induce Focus Formation Without Complete Transformation of NIH 3T3 Cells”Molecular and Cellular Biology, May 1985, pp. 1073-1083, vol. 5, No. 5.
Jones, G. et al. “Development and Validation of a Genetic Algorithm for Flexible Docking”J. Mol. Biol., 1997, pp. 727-748, vol. 267.
Kitas, E. A. et al. “Synthesis of O-Phosphotyrosine-Containing Peptides. 3. Synthesis of H-Pro-Try(P)-Val-OH via Dimethyl Phosphate Protection and the Use of Improved Deprotection Procedures”J. Org. Chen., 1990, pp. 4181-4187, vol. 55.
Kotenko, S. V. et al. “Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes”Oncogene, 2000, pp. 2557-2565, vol. 19.
Lin, T. S. et al. “STAT signaling in the pathogenesis and treatment of leukemias”Oncogene, 2000, pp. 2496-2504, vol. 19.
Lin, J. et al., “The role of Stat5a in Stat5b in signaling by IL-2 family cytokines”Oncogene, 2000, pp. 2566-2576, vol. 19.
Merrifield R. B. “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide”Am. Chem. Soc., Jul. 20, 1963, pp. 2149-2152, vol. 85.
Rojas, M. et al. “Genetic engineering of proteins with cell membrane permeability”Nature Biotechnology, Apr. 1998, pp. 370-375, vol. 16.
Sasse, J. et al. “Mutational Analysis of Acute-Phase Response Factor/Stat3 Activation and Dimerization”Molecular and Cellular Biology, Aug. 1997, pp. 4677-4686, vol. 17, No. 8.
Schindler, C. et al. “Transcriptional Responses to Polypeptide Ligands: The JAK-STAT Pathway”Annu. Rev. Biochem., 1995, pp. 621-651, vol. 64.
Seidel, H. M. et al. “Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity”Proc. Natl. Acad. Sci. USA, Mar. 2, 1995, pp. 3041-3045, vol. 92.
Seidel, H. M. et al. “Pharmaceutical intervention in the JAK/STAT signaling pathway”Oncogene, 2000, pp. 2645-2656, vol. 19.
Shuai, K. et al. “A Single Phosphotyrosine Residue of Stat91 Required for Gene Activation by Interferon-γ”Science, Sep. 24, 1993, pp. 1744-1746, vol. 261.
Shuai, K. et al. “Interferon Activation of the Transcription Factor Stat91 Involves Dimerization through SH2-Phosphotyrosyl
Hamilton Andrew D.
Jove Richard
Sebti Said M.
Turkson James
Gupta Anish
Heard Thomas S.
Saliwanchik Lloyd & Saliwanchik
University of South Florida
LandOfFree
Peptidomimetic inhibitors of STAT activity and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptidomimetic inhibitors of STAT activity and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptidomimetic inhibitors of STAT activity and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3975194